.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Covington
Farmers Insurance
QuintilesIMS
Cerilliant
Cipla
Accenture
US Army
Teva
Chinese Patent Office

Generated: November 18, 2017

DrugPatentWatch Database Preview

Bristol Myers Squibb Company Profile

« Back to Dashboard

What is the competitive landscape for BRISTOL MYERS SQUIBB, and when can generic versions of BRISTOL MYERS SQUIBB drugs launch?

BRISTOL MYERS SQUIBB has seventy-seven approved drugs.

There are eighteen US patents protecting BRISTOL MYERS SQUIBB drugs and there have been three Paragraph IV challenges on BRISTOL MYERS SQUIBB drugs in the past three years.

There are four hundred and fifty-eight patent family members on BRISTOL MYERS SQUIBB drugs in fifty-eight countries and one hundred and seventy-two supplementary protection certificates in fifteen countries.

Summary for Bristol Myers Squibb

International Patents:458
US Patents:18
Tradenames:66
Ingredients:58
NDAs:77
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb
PRAVIGARD PAC (COPACKAGED)
aspirin; pravastatin sodium
TABLET, TABLET, TABLET;ORAL021387-002Jun 24, 2003DISCNNoNo► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
ELIQUIS
apixaban
TABLET;ORAL202155-001Dec 28, 2012RXYesNo► Subscribe► SubscribeYY ► Subscribe
Bristol Myers Squibb
OXYCODONE 5/APAP 500
acetaminophen; oxycodone hydrochloride
TABLET;ORAL085911-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
REYATAZ
atazanavir sulfate
POWDER;ORAL206352-001Jun 2, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
REMSED
promethazine hydrochloride
TABLET;ORAL083176-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
MONOPRIL-HCT
fosinopril sodium; hydrochlorothiazide
TABLET;ORAL020286-002Nov 30, 1994DISCNYesNo► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
ZERIT
stavudine
CAPSULE;ORAL020412-004Jun 24, 1994ABRXYesNo► Subscribe► Subscribe► Subscribe
Bristol Myers Squibb
ZERIT XR
stavudine
CAPSULE, EXTENDED RELEASE;ORAL021453-001Dec 31, 2002DISCNNoNo► Subscribe► SubscribeY► Subscribe
Bristol Myers Squibb
SPRYCEL
dasatinib
TABLET;ORAL021986-006Oct 28, 2010RXYesNo► Subscribe► SubscribeY ► Subscribe
Bristol Myers Squibb
ELIQUIS
apixaban
TABLET;ORAL202155-001Dec 28, 2012RXYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Bristol Myers Squibb

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bristol Myers Squibb
ZERIT
stavudine
CAPSULE;ORAL020412-003Jun 24, 1994► Subscribe► Subscribe
Bristol Myers Squibb
MONOPRIL-HCT
fosinopril sodium; hydrochlorothiazide
TABLET;ORAL020286-001Nov 30, 1994► Subscribe► Subscribe
Bristol Myers Squibb
MONOPRIL-HCT
fosinopril sodium; hydrochlorothiazide
TABLET;ORAL020286-002Nov 30, 1994► Subscribe► Subscribe
Bristol Myers Squibb
VIDEX
didanosine
TABLET, CHEWABLE;ORAL020154-006Oct 28, 1999► Subscribe► Subscribe
Bristol Myers Squibb
VIDEX
didanosine
TABLET, CHEWABLE;ORAL020154-003Oct 9, 1991► Subscribe► Subscribe
Bristol Myers Squibb
BUSPAR
buspirone hydrochloride
TABLET;ORAL018731-003Apr 22, 1996► Subscribe► Subscribe
Bristol Myers Squibb
VIDEX EC
didanosine
CAPSULE, DELAYED REL PELLETS;ORAL021183-004Oct 31, 2000► Subscribe► Subscribe
Bristol Myers Squibb
BUSPAR
buspirone hydrochloride
TABLET;ORAL018731-002Sep 29, 1986► Subscribe► Subscribe
Bristol Myers Squibb
SUSTIVA
efavirenz
TABLET;ORAL021360-001Feb 1, 2002► Subscribe► Subscribe
Bristol Myers Squibb
MONOPRIL-HCT
fosinopril sodium; hydrochlorothiazide
TABLET;ORAL020286-001Nov 30, 1994► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for BRISTOL MYERS SQUIBB drugs

Drugname Dosage Strength Tradename Submissiondate
apixaban
Tablets2.5 mg and 5 mg
ELIQUIS
12/28/2016
efavirenz
Capsules50 mg, 100 mg and 200 mg
SUSTIVA
11/3/2016
naloxone hydrochloride
Nasal Spray4 mg/spray
NARCAN
7/15/2016
dasatinib
Tablets80 mg and 140 mg
SPRYCEL
6/17/2011
dasatinib
Tablets80 mg and 140 mg
SPRYCEL
6/16/2011
dasatinib
Tablets20 mg, 50 mg, 70 mg and 100 mg
SPRYCEL
6/28/2010
entecavir
Tablets0.5 mg and 1 mg
BARACLUDE
6/14/2010
atazanavir sulfate
Capsules100 mg and 150 mg
REYATAZ
3/19/2010
atazanavir sulfate
Capsules200 mg
REYATAZ
2/16/2010
atazanavir sulfate
Capsules300 mg
REYATAZ
7/20/2009
efavirenz
Tablets600 mg
SUSTIVA
4/9/2009
pravastatin sodium
Tablets30 mg
PRAVACHOL
6/1/2005
didanosine
Delayed-release Capsules200 mg, 250 mg and 400 mg
VIDEX EC
6/1/2004

Non-Orange Book Patents for Bristol Myers Squibb

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,979,694 Cyclic protein tyrosine kinase inhibitors► Subscribe
8,470,854Lactam-containing compounds and derivatives thereof as factor XA inhibitors► Subscribe
7,371,761Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
6,110,946 Antivirally active heterocyclic azahexane derivatives► Subscribe
8,188,120Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
RE38629 Solid oral dosage form comprising a combination of metformin and glibenclamide► Subscribe
6,995,172Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
8,716,323Cyclic protein tyrosine kinase inhibitors► Subscribe
7,691,846Lactam-containing compounds and derivatives thereof as factor Xa inhibitors► Subscribe
9,382,219Cyclic protein tyrosine kinase inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Bristol Myers Squibb Drugs

Country Document Number Estimated Expiration
Austria544750► Subscribe
Cyprus2596► Subscribe
Czech Republic293507► Subscribe
Canada2366932► Subscribe
Norway20014970► Subscribe
Russian Federation2006131591► Subscribe
Uruguay25611► Subscribe
Eurasian Patent Organization004515► Subscribe
Germany69732483► Subscribe
Spain2178300► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Bristol Myers Squibb Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB09/026United Kingdom► SubscribePRODUCT NAME: ESTRADIOL AND COMBINATIONS OF ESTRADIOL AND DIENOGEST, PREFERABLY ESTRADIOL VALERATE AND COMBINATIONS OF ESTRADIOL VALERATE AND DIENOGEST; REGISTERED: BE BE 327792 20081103; UK PL 00010/0576-0001 20081208
2006 00038Denmark► SubscribePRODUCT NAME: ETHINYLESTRADIOL (SOM BETA-CYCLODEXTRIN-CLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 38687 20060627; FIRST REG. NO/DATE: EU RVG 31781 20050804
C0002Belgium► SubscribePRODUCT NAME: ESTRADIOL; NAT. REGISTRATION NO/DATE: NL 18978 19960731; FIRST REGISTRATION: SE - 11783 19930305
00567Netherlands► SubscribePRODUCT NAME: DASATINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/06/363/001 .... 009 20061120
C/GB08/040United Kingdom► SubscribePRODUCT NAME: SITAGLIPTIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR THE MONOPHOSPHATE, PLUS METFORMIN OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR THE HYDROCHLORIDE.; REGISTERED: CH 58450 01-03 20080408; UK EU/1/08/455/001 20080716; UK EU/1/08/455/002 20080716; UK EU/1/08/455/003 20080716; UK EU/1/08/455/004 20080716; UK EU/1/08/455/005 20080716; UK EU/1/08/455/006 20080716; UK EU/1/08/455/007 20080716; UK EU/1/08/455/008 20080716; UK EU/1/08/455/009 20080716; UK EU/1/08/455/010 20080716; UK EU/1/08/455/011 20080716; UK EU/1/08/455/012 20080716; UK EU/1/08/455/013 20080716; UK EU/1/08/455/014 20080716
401Luxembourg► SubscribePRODUCT NAME: CLINDAMYCINE(EN TANT QUE PHOPSHATE DE CLINDAMYCINE)ET TRETINOINE
1261586/02Switzerland► SubscribePRODUCT NAME: SAXAGLIPTIN UND METFORMIN; NAT. REGISTRATION NO/DATE: SWISSMEDIC 62040 20120329
90042Netherlands► SubscribePRODUCT NAME: INSULIN ASPART; REGISTRATION NO/DATE: EU/1/99/119/001 - EU/1/99/119/005 19990907
11/024Ireland► SubscribePRODUCT NAME: AZTREONAM LYSINE; REGISTRATION NO/DATE: EU/1/09/543/001 20090923
C0006France► SubscribePRODUCT NAME: DIDANOSINE; NAT. REG.: 203 IS 225 F 3 19930331; FIRST REG.: FR 557 386-4 19920505
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Harvard Business School
Colorcon
UBS
Healthtrust
Deloitte
Boehringer Ingelheim
Fuji
McKesson
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot